- Home
- UAN vs PVLA Comparison
UAN vs PVLA Comparison
Compare UAN & PVLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | UAN | PVLA |
|---|---|---|
| Founded | 2007 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Agricultural Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.1B |
| IPO Year | 2011 | N/A |
Fundamental Metrics
Financial Performance| Metric | UAN | PVLA |
|---|---|---|
| Price | $97.49 | $102.42 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 16 |
| Target Price | N/A | ★ $141.50 |
| AVG Volume (30 Days) | 17.9K | ★ 292.1K |
| Earning Date | 10-29-2025 | 11-11-2025 |
| Dividend Yield | ★ 6.95% | N/A |
| EPS Growth | ★ 141.96 | N/A |
| EPS | ★ 12.04 | N/A |
| Revenue | ★ $614,528,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $8.08 | ★ N/A |
| Revenue Growth | ★ 16.52 | N/A |
| 52 Week Low | $63.45 | $11.17 |
| 52 Week High | $100.89 | $114.69 |
Technical Indicators
Market Signals| Indicator | UAN | PVLA |
|---|---|---|
| Relative Strength Index (RSI) | 59.86 | 56.83 |
| Support Level | $95.05 | $99.00 |
| Resistance Level | $97.20 | $114.69 |
| Average True Range (ATR) | 1.20 | 8.59 |
| MACD | 0.24 | 0.18 |
| Stochastic Oscillator | 85.93 | 62.78 |
Price Performance
Historical ComparisonAbout UAN CVR Partners LP
CVR Partners LP is a manufacturer and supplier of nitrogen fertilizer products. Its principal products include Urea Ammonium Nitrate (UAN) and ammonia. The company market ammonia products to industrial and agricultural customers and UAN products to agricultural customers. The primary geographic markets for its fertilizer products are Kansas, Missouri, Nebraska, Iowa, Illinois, Colorado, and Texas. The company's product sales are heavily weighted toward UAN.
About PVLA Palvella Therapeutics Inc.
Palvella Therapeutics Inc is a late clinical-stage biopharmaceutical company committed to serving individuals suffering from serious, rare genetic skin diseases without approved therapies. The Company's lead product candidate, QTORIN 3.9 percent rapamycin anhydrous gel (QTORIN rapamycin), is based on the Company's patented QTORIN platform. QTORIN rapamycin is in clinical development for two rare genetic skin disorders.